ITGA2B and hemophagocytic syndrome: In the initial phase, this study recruited 9 HLH patients who showed hematological evidence of disease progression while receiving dexamethasone and cyclosporine in combination with anti‐CD41‐PLT‐VP16 treatment (Table S1, Supporting Information).